State of CDMO Quality — Q3 2026
The independent snapshot: rankings, FDA activity, GMP density, and what sponsors should watch.
Executive summary
Q3 2026 opens with the biopharma CDMO industry in a comparatively stable posture on quality but with widening capacity stratification. This report is a data-driven snapshot from CDMO Signal's platform of primary regulatory sources — FDA inspection records, EMA and MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and SEC filings. Every claim in the sections below is traceable to a specific source visible on the ranked CDMO profile pages.
Key findings.
• 383 CDMOs tracked; 166 scored on their available pillars, of which 23 have complete four-pillar scoring and are eligible for the ranked leaderboard. Rankings in this report reflect that four-pillar-eligible subset; the balance are scored but unranked (Operations coverage is still expanding) or profiled without complete Signal Score inputs.
• The excellent tier (Signal Score ≥ 90) contains 3 CDMOs — the narrow set combining top-quartile regulatory posture, capacity depth, and financial stability across the pillars scored.
• GMP certificate density is highly concentrated: the top 10 CDMOs by combined EMA + MHRA certification hold 249 of 534 tracked certificates (46.6%). This is a slow, expensive credential to accumulate — the concentration reflects decades of sustained regulatory engagement, not last-quarter's dealmaking.
• Recent FDA inspection activity (2 inspections in the trailing 90 days) skews toward NAI (no action) classifications — a healthy quarterly signal.
Coverage snapshot & how to read this report
What this report is built on. All counts are live at the time of viewing. The platform updates FDA inspection records daily and re-scores the composite as new source data lands; the specific timestamp of the last score recomputation is shown in the hero above.
Rankings reflect the 23 CDMOs with complete four-pillar scoring. To appear on the ranked leaderboard or a modality top-N, a CDMO must have all four pillars — Quality, Operations, Financial, and Capacity — populated, with Operations backed by real clinical-program data. A further 143 CDMOs are scored on their available pillars (Operations coverage is still expanding across the industry) and appear in profiles and structural findings below, but are not ranked; a partial score is not renormalized to compete with a complete one. The remaining 217 tracked CDMOs are profiled but not yet scored.
Composite order reflects the weighted composite, not any single pillar. A CDMO can rank higher than another despite trailing on Quality alone if Operations, Financial Stability, or Capacity offset — the leaderboard shows all four pillar scores so the order is traceable.
Modality rankings honor small-N with explicit denominators. Where a modality has fewer than 15 fully scored CDMOs, the "top 3" framing is annotated with the total denominator so the reader can weigh the claim appropriately.
Entity attribution reflects current profile state. A CDMO recently involved in a divestiture or spin-off may have its Signal Score reflect the pre-transaction consolidated footprint until source data reallocation completes. Where this applies, an inline note on the ranked row surfaces the caveat; the leaderboard rows below flag any such cases directly.
Structural finding: GMP certificate density is concentrated in the top 10
GMP certificate density — the combined count of EMA EudraGMDP and MHRA GMDP certificates attributed to each CDMO — is the most concrete objective measure of a CDMO's global regulatory posture. Every certificate represents a regulator having formally inspected and authorized a specific site for a specific manufacturing activity. It's a slow, expensive credential to accumulate, which is why the concentration matters: the top 10 CDMOs alone hold 249 of 534 tracked EMA + MHRA certificates (46.6%).
| # | CDMO | EMA | MHRA | Total |
|---|---|---|---|---|
| 1 | Novartis | 64 | 3 | 67 |
| 2 | Catalent | 21 | 16 | 37 |
| 3 | AGC Biologics | 23 | 0 | 23 |
| 4 | FUJIFILM Diosynth Biotechnologies | 17 | 6 | 23 |
| 5 | Pfizer CentreOne | 15 | 3 | 18 |
| 6 | Curia (RNA/Advanced) | 18 | 0 | 18 |
| 7 | Takeda | 18 | 0 | 18 |
| 8 | Bayer (Cell Therapy Mfg) | 16 | 1 | 17 |
| 9 | Oxford Biomedica | 4 | 10 | 14 |
| 10 | BSP Pharmaceuticals | 14 | 0 | 14 |
Why this matters for sponsors. Certificate density isn't a vanity metric. Every EMA or MHRA certificate is scoped to a specific facility and a specific manufacturing activity — so a CDMO with 40+ certificates has demonstrated regulatory readiness across a much broader activity surface than a CDMO with 5. For sponsors evaluating multi-jurisdictional or multi-modality programs, density is a defensible qualifying signal that can't be shortcut by capex.
Structural finding: Signal Score distribution is heavy-tailed, not bell-curved
How all 166 scored CDMOs distribute across the composite Signal Score 0–100 range (the full scored population — including CDMOs scored on a partial pillar set, not only the 23 four-pillar-eligible entities that appear on the ranked leaderboard). The distribution is meaningfully asymmetric — a heavy tail at the excellent and strong tiers reflects the industry's actual quality stratification. This is not a bell curve; the biopharma CDMO industry has real, measurable gaps between top-tier and long-tail providers, and Signal Score surfaces them by design.
How to read this. The Excellent tier (≥ 90) is the narrowest by design — a CDMO needs top-quartile scores across all four pillars to land there. The Strong tier (80–89) is where the bulk of well-established CDMOs cluster. The Watch tier (< 60) is not a red flag on its own; it usually indicates thin regulatory data (a CDMO with a narrow public inspection or certificate record) rather than genuine quality concerns. The unscored balance of the directory (217 CDMOs) is not shown here — those are profiled but haven't yet accumulated the four-pillar inputs required for scoring.
FDA inspection activity — last 90 days
Recent FDA inspection outcomes across the tracked CDMO set. The classification breakdown is the most reliable near-term signal on industry quality trajectory — a NAI-heavy quarter indicates the industry is maintaining compliance under regulator scrutiny; a shift toward VAI or OAI indicates emerging quality issues that sponsors should investigate.
NAI-heavy quarters may reflect FDA prioritizing lower-risk sites for its post-pandemic inspection backlog rather than genuine industry-wide improvement. The trajectory to watch is when OAI classifications return to their pre-2020 baseline rate, which will reset how sponsors weight inspection recency in vendor selection.
Recent inspections
| Date | CDMO | Site | Classification |
|---|---|---|---|
| 2026-06-30 | Thermo Fisher Scientific | Greenville, North Carolina | ● NAI |
| 2026-06-17 | Cytovance Biologics | Oklahoma City, Oklahoma | ● VAI |
Warning Letter footprint
Warning Letters are the most serious FDA regulatory communication and stay on the record indefinitely. This section surfaces the small set of CDMOs in our tracked universe with public Warning Letter history. A single Warning Letter is a serious event; recurring Warning Letters across multiple years are the strongest publicly available quality signal — and the reason the Signal Score's Quality Compliance pillar weighs Warning Letter history heavily.
| # | CDMO | Warning Letters |
|---|---|---|
| 1 | Intas Pharmaceuticals | 6 |
| 2 | Catalent | 2 |
| 3 | Simtra BioPharma Solutions | 2 |
Full composite leaderboard — top 15 by Signal Score
The top 15 CDMOs by composite Signal Score across all four pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%). Every pillar score is visible so the composite order is traceable. Where a CDMO's Signal Score reflects a consolidated entity that lags a recent corporate action (spin-off, divestiture), an inline note flags the caveat directly on the row.
| # | CDMO | Composite | Quality | Ops | Fin | Capacity |
|---|---|---|---|---|---|---|
| 1 |
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
|
91.5 | 100.0 | 93.8 | 89.0 | 76.0 |
| 2 |
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
|
90.8 | 97.0 | 95.2 | 89.0 | 76.0 |
| 3 |
Novartis
Basel, Switzerland
|
88.3 | 90.9 | 94.8 | 78.0 | 86.0 |
| 4 |
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
|
84.8 | 100.0 | 75.1 | 88.0 | 67.0 |
| 5 |
City of Hope (T Cell Manufacturing)
Duarte, CA
|
83.8 | 96.8 | 98.9 | 68.0 | 58.0 |
| 6 |
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
83.1 | 97.9 | 60.0 | 78.0 | 91.0 |
| 7 |
Moderna (Contract Mfg)
Norwood, MA
|
81.8 | 100.0 | 63.0 | 89.0 | 66.0 |
| 8 |
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.6 | 72.3 | 83.0 | 63.0 |
| 9 |
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 60.0 | 75.0 | 78.0 |
| 10 |
Takeda
Boston, MA · Zurich, CH
|
80.5 | 99.3 | 84.7 | 60.0 | 63.0 |
| 11 |
Bayer (Cell Therapy Mfg)
Berkeley, CA
|
79.2 | 86.9 | 94.5 | 68.0 | 58.0 |
| 12 |
Novartis Contract Manufacturing
Morris Plains, NJ · Stein, CH
|
79.1 | 90.9 | 94.8 | 60.0 | 58.0 |
| 13 |
Cedars-Sinai Biomanufacturing
Los Angeles, CA
|
78.9 | 100.0 | 75.0 | 68.0 | 58.0 |
| 14 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 50.0 | 75.0 | 87.0 |
| 15 |
Codiak BioSciences (Sarepta)
Cambridge, MA
|
78.0 | 100.0 | 60.0 | 74.0 | 66.0 |
Modality leaders — top 3 per modality
Top CDMOs per tracked modality, ranked by composite Signal Score. Only four-pillar-eligible CDMOs (all pillars populated) are ranked, so a modality's denominator is its eligible count, not every CDMO tagged to it. Sponsors typically look at their specific modality first; the same CDMO can lead in one modality without being competitive in another, and specialization often matters as much as scale. Every card shows the eligible count for that modality — a "top 3 of 32 eligible" claim is materially different from "top 2 of 2 eligible", and the framing makes the distinction explicit.
Cards flagged in amber ("of <10 eligible") indicate a modality with a thin four-pillar-eligible denominator — either because the segment is genuinely small (e.g. commercial exosome CDMOs), because our coverage is still building, or because most CDMOs in that segment are not yet fully four-pillar scored (Operations coverage is still expanding). In either case, treat the ranking as directional rather than definitive; the specialists who know that segment cold will have peers not yet ranked on this list.
What we're watching next quarter
Three structural themes we're tracking into Q4 2026, based on the platform's data flow and monitored press.
The last 24 months have seen substantial commercial-scale capacity announcements in AAV, lentiviral vector, and mRNA manufacturing. Whether that capacity translates into validated commercial supply — versus paper capacity that never materializes — is the key operational question. We watch the Capacity Intelligence pillar for facility-opening confirmations and validated batch scale-up.
With the wave of approved ADCs (Enhertu, Trodelvy, Elahere, Tivdak) and dense clinical pipelines, ADC CDMO capacity remains a bottleneck. Expect continued M&A in the integrated ADC segment. The ADC CDMO ranking and its filter sub-paths track this.
Post-pandemic FDA inspection cadence is still not fully normalized, particularly for foreign sites. Recent NAI-heavy classifications may partially reflect the FDA prioritizing lower-risk sites for its backlog; the trajectory to watch is when OAI classifications return to their pre-2020 baseline rate, which will reset how sponsors weight inspection recency in vendor selection.
Methodology & sources
All data cited in this report is drawn from CDMO Signal's platform of primary regulatory and operational sources: FDA Data Dashboard inspection records (Establishment Inspection Reports, Form 483 observations, Warning Letters), EMA EudraGMDP and MHRA GMDP certificate registries, ClinicalTrials.gov sponsor/site records, SEC EDGAR filings, and monitored trade press.
Signal Score is a 0–100 composite of four weighted pillars: Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%). CDMOs cannot pay to influence their scores; there is no sponsored placement in any ranking on the platform.
For the complete methodology, weight derivations, and per-source disclosures, see cdmosignal.com/methodology. Rankings and counts in this report reflect the live platform state; the timestamp of the most recent Signal Score recomputation appears in the report hero.
How to cite this report
Please cite as:
CDMO Signal. "State of CDMO Quality — Q3 2026." Published 2026-07-18. Retrieved from https://cdmosignal.com/reports/state-of-cdmo-quality-2026-q3.
For journalists, analysts, or research groups: additional data extracts and methodology detail are available on request at hello@cdmosignal.com.